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Summary
Two decades ago the introduction of cisplatin-based
combination chemotherapy has dramatically improved
the prognosis of patients with metastatic testicular
cancer. At present 3 cycles of cisplatin, etoposide and
bleomycin are considered as standard treatment for
good-risk metastatic disease. Outside of clinical trials
patients in the intermediate and poor prognosis cate-
gories should receive 4 cycles of this standard regimen.
Clinical trials currently evaluate the role of high-dose che-
motherapy in first-line treatment of high-risk patients and
in the salvage setting. Post-chemotherapy resection of
tumor residuals remains an important part of therapy.
Attention should be focused on long-term toxicity of
therapy and the occurrence of late relapse.
Schlüsselwörter
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Zusammenfassung
Vor zwei Jahrzehnten hat die Einführung cisplatinhaltiger
Kombinationschemotherapie die Prognose von Patienten
mit metastasiertem Hodentumor erheblich verbessert.
Gegenwärtig werden 3 Zyklen Cisplatin, Etoposid und
Bleomycin als Standardtherapie für Patienten mit progno-
stisch günstiger Metastasierung angesehen. Außerhalb
von klinischen Studien sollten Patienten mit intermediä-
rer und ungünstiger Prognose 4 Zyklen dieses Standard-
protokolls erhalten. Klinische Studien untersuchen derzeit
die Rolle der Hochdosischemotherapie als Ersttherapie
für Hochrisikopatienten und bei rezidivierter Erkrankung.
Die Resektion von Tumorresiduen nach Chemotherapie
bleibt ein wichtiger Bestandteil der Therapie. Der lang-
fristigen Toxizität der Therapie und dem Vorkommen von
Spätrezidiven sollten Aufmerksamkeit geschenkt werden.
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Introduction
Testicular germ cell tumor is a relatively rare neoplasm,
accounting for only 1–2% of malignancies in adult men [1].
However, testicular cancer is the most common solid tumor in
the third and fourth decade of life. Presently, approximately
3,000 new cases per year are diagnosed in Germany. The in-
cidence varies according to geographic area; it is highest in
Scandinavia followed by Germany and New Zealand. Over the
past five decades the incidence has doubled every 20 years.
History of Chemotherapy
Around four decades ago testicular cancer was recognized 
as a chemosensitive tumor. Combination chemotherapy con-
sisting of dactinomycin, methotrexate, and chlorambucil led to
a 50% response rate in metastatic disease, and 5–10% of pa-
tients attained long-term disease-free survival [2]. Some
improvement was achieved by using a combination of vin-
blastine and bleomycin; the cure rate rose to 25% [3]. How-
ever, the major breakthrough in the history of chemotherapy
for testicular cancer was the discovery of cisplatin by Rosen-
berg and coworkers [4]. In early clinical trials cisplatin proved
to be toxic with only modest activity in various solid tumors
when used in heavily pretreated patients. Higby et al. [5] first
evaluated the activity of cisplatin in pretreated testicular cancer
patients, and reported 3 complete and 3 partial remissions in
11 patients.
In 1974 Einhorn and Donohue [6] added the experimental
drug cisplatin to the established regimen of vinblastine and
bleomycin. Patients received 4 courses of the combination cis-
platin, vinblastine, and bleomycin followed by maintenance
chemotherapy consisting of 0.3 mg/kg vinblastine monthly for
2 years. Of the first 47 patients 33 (70%) achieved complete
response and an additional 5 (11%) were rendered disease-free
by post-chemotherapy resection of residual masses [6]. This
combined modality approach also was novel, and required uro-
logical and thoracic surgical expertise. A subsequent random-
ized trial demonstrated no benefit for maintenance therapy; the
relapse rate after complete response to four cycles of induction
chemotherapy was only 5% with or without maintenance
vinblastine [7]. In Germany cisplatin-based chemotherapy for
testicular cancer was introduced in 1979.
In 1980 Fitzharris et al. [8] documented the single-agent activity
of etoposide in refractory testicular cancer. Thereafter, a ran-
domized trial compared the combination of cisplatin 20 mg/m2
(days 1–5) and bleomycin 30 mg (days 2, 9, 16) with either
vinblastine 0.15 mg/kg (days 1, 2) or etoposide 100 mg/m2 (days
1–5) as first-line treatment for metastatic testicular cancer [9].
In the etoposide arm there was a major reduction of neuro-
muscular toxicity. Moreover, in the worst prognostic subgroup
there was a survival advantage for cisplatin, etoposide, and
bleomycin (PEB). Since 1987 this combination has been used
as standard first-line chemotherapy for metastatic testicular
cancer.
Summarizing 5 early studies of ifosfamide in patients without
pretreatment with cisplatin there was a response rate of 65%,
a complete response rate of 20%, and a number of durable
complete responses of 2.5–8 years [10]. In the setting of prior
cisplatin-based chemotherapy the activity of ifosfamide was
considerably lower with a 20% overall response rate and only
a 1% complete response rate. Whereas ifosfamide is now a
component of many salvage protocols, its role in first-line
therapy of testicular cancer still has to be defined.
In the following sections current strategies and future perspec-
tives for the treatment of testicular cancer are discussed. As
nonseminomatous tumors and pure seminomas have a dif-
ferent biological behavior with consequences for treatment,
both entities are presented separately.
Nonseminomatous Germ Cell Tumor
Adjuvant Chemotherapy
The high activity of cisplatin-based chemotherapy in metastatic
disease led to its evaluation in the adjuvant setting. Whereas
patients with resected stage IIA/B testicular cancer (retro-
peritoneal lymph nodes less than 5 cm in diameter) develop
recurrent disease in around 50% on surveillance, 2 cycles of
standard chemotherapy almost always prevent relapse [11].
In recent years some investigators propagated adjuvant
chemotherapy for high-risk stage I disease. Almost three
quarters of patients with stage I disease belong to a low-risk
group with a risk of relapse of less than 20%; these patients are
set on a surveillance protocol with chemotherapy reserved for
relapse. The remaining patients with high-risk features (histo-
pathologic criteria) carry a risk of relapse of around 50%;
2 cycles of adjuvant chemotherapy reduce the recurrence rate
to less than 5% [12].
Chemotherapy for Metastatic Disease
As an alternative to bilateral retroperitoneal lymph node dis-
section some investigators evaluated primary chemotherapy
for stage IIA/B disease [12]. Approximately two thirds of
patients achieve a complete response to 3 (to 4) cycles of
standard chemotherapy.The remaining patients have to under-
go post-chemotherapy resection of residual masses. Thus a
considerable proportion of patients is spared the morbidity of
a surgical intervention by this approach, but a relapse rate of
around 10% is higher than for retroperitoneal lymph node
dissection followed by adjuvant chemotherapy. Nevertheless,
similar survival rates between 95 and 100% were reported for
both treatment options [12].
Patients with retroperitoneal lymph node metastases greater
than 5 cm in diameter, supradiaphragmatic lymph node in-
volvement or visceral metastases undergo chemotherapy as
first treatment modality. According to the International Germ
Cell Cancer Collaborative Group (IGCCCG) patients are
divided into 3 prognostic categories (table 1) [13]. Prognostic
factors include the levels of the tumor markers human
chorionic gonadotropin (HCG) and alpha-fetoprotein (AFP)
and lactate dehydrogenase (LDH) as well as rare tumor sites.
In the large cohort of more than 5,000 patients of the IGCCCG
study 56% of the patients belonged to the good-risk group with
a 5-year survival rate of 91%. The intermediate-risk group
comprised 28% of the cohort, and was characterized by a 
5-year survival rate of 79%. The poor-risk group constituted
16% of the patients with a 5-year survival of only 48%.
As a randomized trial comparing 4 versus 3 cycles of standard
chemotherapy in minimal and moderate disease according to
Indiana University classification demonstrated no difference
in response and survival rates, 3 cycles of PEB are currently
considered as standard treatment for good-risk patients [14].
Recently, an EORTC/MRC phase III study comparing 3 versus
4 cycles of standard chemotherapy in IGCCCG good-risk pa-
tients confirmed the equivalence [15]. In poor-risk patients
neither doubling of the cisplatin dose nor substitution of ifos-
famide for bleomycin led to an improvement of outcome [16,
17]. Outside of clinical trials patients in the intermediate and
poor-risk categories should receive 4 cycles of PEB.
There is some evidence that survival rates for patients in the
intermediate and poor-risk categories improved during the
cisplatin era. Substitution of etoposide for vinblastine, cumula-
tive experience, advances in supportive care and treatment
intensification have been discussed as contributory factors [18].
However, the role of dose-intensified therapy is difficult to
define. The only randomized trial that compared PEB with a
sequential dose-intensified regimen (BOP/VIP-B: bleomycin,
vincristine, cisplatin/etoposide, ifosfamide, cisplatin-bleo-
mycin) could not demonstrate a survival advantage for the
experimental arm [19]. However, the lack of superiority of the
BOP/VIP-B protocol might be due to its composition: the
doses of etoposide (VP-16) and ifosfamide were 20–25%
lower than in other VIP protocols. Furthermore, almost 50% of
patients had moderate dose reductions. Recently reported
retrospective studies suggested that treatment intensification
might improve clinical outcome of poor-risk patients. For the
cyclical protocol POMB/ACE (cisplatin, vincristine, methotrex-
ate, bleomycin/ actinomycin D, cyclophosphamide, etoposide)
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a 3-year survival rate of 75% was reported for poor-risk
patients compared to 50% in the IGCCCG study [20]. A
German multicenter study performed a stepwise dose escala-
tion of etoposide and ifosfamide in the PEI (cisplatin, eto-
poside, ifosfamide) protocol with stem cell support. A recent
matched-pair analysis comparing high-dose PEI with standard-
dose PEB or PEI demonstrated a significant survival ad-
vantage for first-line high-dose chemotherapy (3-year survival
80 vs. 61%, p = 0.02) [21]. In the United States a randomized
trial currently compares 4 cycles of PEB with 2 cycles of PEB
followed by 2 cycles of high-dose carboplatin, etoposide and
cyclophosphamide in intermediate and poor-risk patients.
Nonseminomatous germ cell tumors in the intermediate and
poor-risk categories are rare. Some studies demonstrated that
referral to a specialist unit significantly improves survival 
[22, 23]. Moreover, a recent international study showed that
treatment-related deaths were more frequent at hospitals that
treated less than 5 cases compared with centers that treated 
20 or more patients (13 vs. 3%) [19].
Post-Chemotherapy Surgery
After the end of chemotherapy a considerable proportion of
patients shows residual masses at CT scans. These residual
masses consist of necrosis/fibrosis, mature teratoma or viable
cancer [24]. In two large series necrosis/fibrosis was found in
45%, mature teratoma in 42% and viable cancer in 13% of
retroperitoneal tumor residuals [25, 26]. Resection of tumor
residuals containing necrosis/fibrosis is only a diagnostic
procedure. In contrast, resection of mature teratoma or viable
cancer provides a therapeutic benefit. For almost two decades
it has been standard at many institutions to give 2 further
cycles of chemotherapy to patients with resected viable
cancer, although there was no consensus whether chemo-
therapy should be applied according to the induction protocol
or an alternative regimen. Recently, a retrospective interna-
tional study demonstrated that additional chemotherapy in
patients with resected viable cancer improved progression-
free survival but did not have a significant impact on overall
survival [27].
Approximately one third of patients shows tumor residuals in
multiple anatomic sites, for example in the retroperitoneum
and the lungs [28]. Some investigators advocate complete re-
section of all tumor residuals if technically feasible [29]. How-
ever, in an international study 48 of 54 patients (89%) with
necrosis at retroperitoneal lymph node dissection had the
same favorable histology at thoracotomy [30]. These data
suggest that the benefit of a second or third surgery is low if
there is necrosis/fibrosis in the resected retroperitoneal mass.
Because of the high predictive value of the histology in the
retroperitoneal space retroperitoneal lymph node dissection
should usually precede thoracotomy.
Salvage Treatment
Patients who need salvage chemotherapy for refractory or
recurrent disease carry a relatively poor prognosis. After con-
ventional salvage treatment (cisplatin-ifosfamide-based chemo-
therapy with either vinblastine or etoposide) only 20–30% 
of patients attain long-term disease-free survival [31, 32]. A
recent study identified the following unfavorable prognostic
factors after conventional salvage treatment: incomplete re-
sponse to first-line chemotherapy, time to progression less than
2 years, high levels of tumor markers (HCG >100 U/l or
AFP >100 U/ml) [33]. Patients with all 3 poor-risk features con-
stituted one quarter of the entire group. Prognosis was dismal
in this subgroup, no patient was alive 3 years after the start of
salvage treatment. The remaining three quarters of patients
with no more than 2 poor-risk factors attained a 5-year survival
rate of around 50%.
As high-hose chemotherapy with autologous bone marrow
rescue achieved durable responses in around 15% of heavily
pretreated patients (third-line or later) in early studies [34], this
treatment option is now increasingly used as first salvage treat-
ment. In a recent study that included 49 patients with first
relapse, 25 patients (51%) were continuously disease-free after
a minimal follow-up of 12 months after high-dose chemotherapy
[35]. However, patients with extragonadal primaries, who carry
a less favorable prognosis than patients with testicular tumors,
were excluded from this study. Recently, a matched-pair
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Table 1. International consensus classification for metastatic germ cell cancers
Prognostic category Seminoma Nonseminoma_____________________________________________ __________________________________________________________________________________
metastases site tumor marker metastases site
Good-risk no non-pulmonary any primary site AFP < 1,000 ng/ml no non-pulmonary testicular/retroperitoneal
visceral metastases HCG < 5,000 U/l visceral metastases primary site
LDH < 1.5 · N*
Intermediate-risk non-pulmonary any primary site AFP 1,000–10,000 ng/ml no non-pulmonary testicular/retroperitoneal
visceral metastases HCG 5,000–50,000 U/l visceral metastases primary site
LDH 1.5–10 · N*
Poor-risk – – AFP > 10,000 ng/ml non-pulmonary mediastinal primary site
HCG > 50,000 U/l visceral metastases
LDH > 10 · N* (bone, liver, brain)
*N = Upper limit of normal range.
analysis comparing conventional chemotherapy and high-dose
chemotherapy at first relapse, showed a small but significant
survival advantage for patients receiving high-dose chemo-
therapy [36]. A European study prospectively compares
conventional and high-dose chemotherapy for patients with
favorable prognostic features at first relapse; patient accrual is
ongoing. Recently, a German phase III trial started that in-
cludes patients at first and subsequent relapses. One arm
consists of 3 cycles of standard salvage therapy followed by 
1 cycle of high-dose carboplatin, etoposide, and cyclophospha-
mide. Patients randomized to the other arm receive 1 cycle of
standard salvage therapy followed by 3 cycles of high-dose
carboplatin and etoposide.
Despite the encouraging results in some studies, high-dose
chemotherapy for testicular cancer should be still regarded as
an investigational approach. This treatment should be given
only at specialist centers and only in the setting of a clinical
trial.
As a considerable proportion of patients develops relapse after
high-dose chemotherapy, the evaluation of new drugs still plays
a major role in clinical investigations of testicular cancer.
Recent studies identified paclitaxel and gemcitabine as active
agents in testicular cancer with response rates of around 20%
in heavily pretreated patients [37, 38]. In clinical trials pacli-
taxel has been already incorporated in first-line and salvage
chemotherapy protocols. German phase II studies currently
evaluate the activity of bendamustine and oxaliplatin in
heavily pretreated patients.
Late relapses of testicular cancer are defined as recurrences
after a relapse-free interval of more than 2 years after dis-
continuation of primary therapy. Unselected patients appear-
ing disease-free at 2 years have a cumulative risk of late relapse
of about 4% at 10 years [39]. Patients with a high tumor burden
at the start of primary chemotherapy carry a substantially
higher risk for late relapse than patients with a small-volume
disease. Late relapses are often resistant to chemotherapy.




Seminomas are characterized by a less aggressive biological
behavior than nonseminoma and predominant lymphoge-
nous dissemination. Approximately 85% of patients present
with clinical stage I disease. As almost 20% of stage I patients
have occult retroperitoneal lymph node metastases, prophy-
lactic para-aortic radiotherapy is recommended as standard
treatment [40]. As an alternative to radiotherapy, adjuvant
chemotherapy with carboplatin, a less toxic platinum com-
pound than cisplatin, is currently evaluated in clinical trials.
One study group propagates surveillance for stage I semi-
noma patients with radiotherapy or chemotherapy reserved
for relapse [41].
Treatment of stage IIA/B seminoma is also a domain of radio-
therapy [41]. Around 15% of stage IIB patients (retroperi-
toneal lymph nodes between 2 and 5 cm in diameter) develop
a relapse outside of the irradiated field; a high proportion of
these patients can be successfully salvaged by cisplatin-based
chemotherapy. Prognosis of stage I and IIA/B seminoma
patients is excellent with long-term survival rates between 95
and 100%.
Advanced Stages
Patients with stage IIC/D seminoma (retroperitoneal lymph
nodes greater than 5/10 cm) develop relapses after radio-
therapy in a proportion of around 50%. There is now a con-
sensus that these patients should receive cisplatin-based
chemotherapy as first-line therapy, as well as patients with
supradiaphragmatic lymph node involvement or visceral
metastases [41]. Patients with lymph node and/or lung metas-
tases attain long-term disease-free survival rates of around 90%.
The small number of patients with non-pulmonary visceral
metastases belongs to the intermediate-risk group according 
to IGCCCG criteria with a cure rate between 70 and 80%. A
German multicenter trial currently compares the efficacy of a
combination of etoposide, ifosfamide and cisplatin with single
agent carboplatin in advanced seminoma. Post-chemotherapy
resection of residual masses plays a minor role in seminoma
compared with nonseminoma. One study group recommends
resection of masses greater than 3 cm [42]. Other investigators
prefer a policy of close observation [43].
Late Toxicity
As patients cured from testicular cancer expect an additional
50 years to live, late toxicity is of major interest. Recently, we
described a remarkable storage of platinum in chemotherapy-
treated long-term survivors of testicular cancer [44]. At
5.3–16.8 years after chemotherapy urinary platinum excretion
and serum platinum levels were 100 to 1,000 times higher in
patients than in unexposed controls.
In a study that included 90 patients with a median follow-up 
of 58 months after chemotherapy, most frequent symptomatic
toxicities were Raynaud’s phenomenon in 30% of patients,
ototoxicity in 21%, and peripheral neuropathy in 17% [45].
These toxicities were significantly more frequent in patients
who had received a cumulative cisplatin dose higher than 
400 mg/m2.
Fertility is another important issue. A recent study docu-
mented that spermatogenesis is already impaired in men with
testicular cancer before orchiectomy [46]. The most likely
explanation is preexisting impairment of spermatogenesis in
the contralateral testis in men with testicular cancer. Cisplatin-
based chemotherapy has an additional adverse effect on
spermatogenesis which is only in part reversible [47]. Normo-
spermia before chemotherapy was recognized as favorable
prognostic factor for recovery of spermatogenesis after
chemotherapy. Patients receiving a cumulative cisplatin dose
higher than 400 mg/m2 had unfavorable prospects of fertility.
Sperm banking should be offered to testicular cancer patients
prior to start of chemotherapy.
Presently, there is no consensus whether chemotherapy for
testicular cancer leads to an increase of cardiovascular risk.
Some studies described elevated serum cholesterol levels after
cisplatin-based chemotherapy, whereas other investigators
could not confirm this finding [48]. Another question is
whether cisplatin-based chemotherapy leads to an increase of
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second cancer risk. In animal models, platinum causes solid
tumors, as well as leukemia. Travis et al. [49] described a signif-
icantly elevated risk of second malignant neoplasms for more
than two decades following radiotherapy or chemotherapy for
testicular cancer. This study could not clarify the role of cis-
platin. However, a recent case-control study demonstrated an
increased risk of leukemia after platinum-based chemotherapy
for ovarian cancer [50]. Moreover, in testicular cancer the use
of etoposide adds to the risk of leukemia.
Conclusions
Two decades after introduction of cisplatin-based chemothera-
py for testicular cancer many questions have been answered by
clinical studies. Present issues include improvement of therapy
for poor-risk metastatic disease, salvage chemotherapy strate-
gies and indications for resection of residual masses after che-
motherapy. Attention should be also focused on long-term
toxicity and the occurrence of late relapse.
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